Evaluate the Safety and Exploratory Efficacy of GC1119
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and exploratory efficacy of GC1119
(recombinant human α-galactosidase A) for enzyme replacement therapy in Fabry disease
patients.